The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 12, 2015
Filed:
Dec. 07, 2005
Malcolm Andrew Ward, Shefford, GB;
John Collinge, London, GB;
Graham Stuart Jackson, Drayton, GB;
Emma Mcgregor, London, GB;
Nicola Louise Leeds, Tonbridge, GB;
James Campbell, London, GB;
Jules Arthur Westbrook, Middlesex, GB;
Helen Louise Byers, London, GB;
Malcolm Andrew Ward, Shefford, GB;
John Collinge, London, GB;
Graham Stuart Jackson, Drayton, GB;
Emma McGregor, London, GB;
Nicola Louise Leeds, Tonbridge, GB;
James Campbell, London, GB;
Jules Arthur Westbrook, Middlesex, GB;
Helen Louise Byers, London, GB;
Electrophoretics Limited, Cobham Surrey, GB;
Medical Research Council, London, GB;
University College London, London, GB;
Abstract
The invention relates to a method of diagnosis of vCJD in a diagnostic sample of a valid body tissue taken from a human subject, which comprises detecting an increased concentration of a protein in the diagnostic sample, compared with a sample of a control human subject, the protein being: beta-actin (SwissProt Acc. No. P60709), apolipoprotein A-IV precursor (SwissProt Acc. No. P06727); haptoglobin beta-chain consisting of residues 162-406 (SwissProt Acc. No. P00738); haemoglobin beta chain (SwissProt Acc. No. P02023); or alpha-1-antitrypsin (SwissProt Acc. No. P01009); or a decreased concentration of a protein in the diagnostic sample, compared with a sample of a control, normal human subject, the protein being plasma protease (C1) inhibitor precursor (SwissProt Acc. No. P05155); complement component 1, s sub-component (SwissProt Acc. No. P09871); butyrylcholinesterase precursor (SwissProt Acc. No. P06276); complement component C4B (SwissProt Acc. No. P01028); lumican (SwissProt Acc. No. P51884); alpha-fibrinogen precursor (SwissProt Acc. No. P02671); IGHG4 protein (Swiss Prot Acc. No. Q8TC63) or immunoglobulin lambda heavy chain. Other marker proteins are also disclosed.